- Marker Therapeutics Inc to Participate in the Beyond CAR-T: What's Next for Cell Therapy Event TranscriptAug 09, 2023
- Marker Therapeutics Inc to Host Clinical Program Update Call TranscriptFeb 16, 2022
- Marker Therapeutics Inc at Raymond James Human Health Innovation Conference (Virtual) TranscriptJun 21, 2021
- Q1 2021 Marker Therapeutics Inc Earnings Call TranscriptMay 12, 2021€19.1 (-1.04%)Earnings
- Q3 2020 Marker Therapeutics Inc Earnings Call TranscriptNov 09, 2020€12.7 (+8.55%)Earnings
- Marker Therapeutics Inc MultiTAA-Specific T Cell Therapy in Patients with Pancreatic Adenocarcinoma at the 2020 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting TranscriptJun 01, 2020
- Q1 2020 Marker Therapeutics Inc Earnings Call TranscriptMay 11, 2020€22.8 (+8.57%)Earnings
- Q3 2019 Marker Therapeutics Inc Earnings Call TranscriptNov 12, 2019€35.64 (-0.03%)Earnings
- Marker Therapeutics Inc Special Call TranscriptJul 22, 2019
- Marker Therapeutics Inc at Bank of America Merrill Lynch Health Care Conference TranscriptMay 16, 2019
Marker Therapeutics Inc Special Call Transcript
Good morning and welcome to the Marker Therapeutics Conference Call. This is Tony Kim, Chief Financial Officer of Marker Therapeutics. The press release containing the interim study results with our MultiTAA therapy in pancreatic cancer as reported over the weekend at AACR are available in the News and Media section of the Marker Therapeutics' website.
Joining me for the call today are Peter Hoang, our Chief Executive Officer; Juan Vera, our Co-Founder and Chief Development Officer; Mythili Koneru, our Senior Vice President of Clinical Development, and Dr. Brandon Smaglo, lead investigator for the TACTOPS study and the System Professor and Medical Director of Oncology at Baylor College of Medicine.
As a reminder, we will be making forward-looking statements. These statements are subject to risks and uncertainties and may cause actual results to materially differ from those forecasted. A description of these risks can be found in our most recent Form 10-Q on file with the SEC.
I would like to turn the call over to Peter Hoang, our
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)